Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innate Pharma SA ( (FR:IPH) ) has issued an update.
Innate Pharma S.A., a clinical-stage biotechnology company specializing in immuno-oncology, develops differentiated antibody-based therapies aimed at cancers with high unmet medical need. Its pipeline includes first- or best-in-class candidates such as the Nectin-4 antibody-drug conjugate IPH4502 for solid tumors, lacutamab for cutaneous and peripheral T cell lymphomas, and monalizumab in non-small cell lung cancer in collaboration with AstraZeneca.
On March 19, 2026, Innate Pharma announced it will host a conference call and webcast on March 26, 2026 to discuss its full-year 2025 financial results. The event, led by CEO Jonathan Dickinson and the senior management team, underscores ongoing engagement with investors as the company advances its oncology pipeline, and may provide stakeholders with updates on clinical progress, partnerships and financial runway.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing cancer immunotherapies. Leveraging antibody engineering and novel target identification, it is advancing next-generation antibody therapeutics such as IPH4502, lacutamab and monalizumab for solid tumors and various T cell lymphomas, often in collaboration with partners including AstraZeneca and Sanofi.
Headquartered in Marseille with a U.S. office in Rockville, Md., Innate Pharma targets areas of high unmet medical need in immuno-oncology. The company is dual-listed on Euronext Paris and Nasdaq, under the tickers IPH and IPHA respectively, and maintains research partnerships with leading academic and research institutions to bolster its pipeline.
Average Trading Volume: 161,159
Technical Sentiment Signal: Sell
Current Market Cap: €110.6M
Find detailed analytics on IPH stock on TipRanks’ Stock Analysis page.